SCHEMBL7906473

SCHEMBL7906473

CC(C)(C)OC(=O)CC[C@H](NC(=O)Cc1ccc(N(CCCl)CCCl)cc1)C(=O)OC(C)(C)C

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.52
LMNA P02545 3/20 0.43
HDAC6 Q9UBN7 2/20 0.41
NPSR1 Q6W5P4 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
CNR2 P34972 3/20 0.38
ALDH1A1 P00352 3/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
HIF1A Q16665 3/20 0.38
MAPT P10636 2/20 0.38
NFKB1 P19838 2/20 0.38
THPO P40225 2/20 0.38
PMP22 Q01453 2/20 0.38
GMNN O75496 1/20 0.38
CYP2D6 P10635 1/20 0.38
GABRA1 P14867 1/20 0.38
TSHR P16473 1/20 0.38
GABRA2 P47869 1/20 0.38
GABRB2 P47870 1/20 0.38
SLCO1B3 Q9NPD5 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7900272 0.91 KMT2A (0.41) KMT2ALMNANPSR1L3MBTL1CNR2
SCHEMBL9751830 0.85 EGFR (0.45) LMNAHDAC6
SCHEMBL7902718 0.82 CNR2 (0.40) KMT2AL3MBTL1CNR2TDP1HDAC8
SCHEMBL8722824 0.81 TYMS (0.37) LMNA
SCHEMBL8723902 0.81 KMT2A (0.64) KMT2ALMNAHDAC6NPSR1L3MBTL1
SCHEMBL8726309 0.80 KMT2A (0.61) KMT2ALMNAHDAC6NPSR1L3MBTL1
SCHEMBL8509781 0.78 LMNA (0.33) KMT2ALMNACA12CA1CA2
SCHEMBL7902794 0.78 KMT2A (0.47) KMT2ALMNAALDH1A1MAPTMEN1
SCHEMBL8726196 0.76 CYP3A4 (0.46) KMT2ALMNAHDAC6ALDH1A1SMN1; SMN2
SCHEMBL7902134 0.76 PPARG (0.34) KMT2ALMNAALDH1A1SMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6277880-B1 ANTIBODY DIRECTED ENZYME PRODUG THERAPY ZENECA LIMITED (GB) 2001-08-21 US disclosed
EP-0651740-B1 AMINO ACID LINKED NITROGEN MUSTARD DERIVATIVES AND THEIR USE AS PRODRUGS IN THE TREATMENT OF TUMOURS ZENECA LTD (GB) 1998-10-21 EP disclosed
US-5660829-A DEESTERIFYING COMPOUND TO FORM N-(4(N,N-BIS(2-CHLOROETHYL) AMINO)PHENOXYCARBONYL)-L-GLUTAMIC ACID-GAMMA-(3,5-DICARBOXY)ANILIDE ZENECA LIMITED (GB) 1997-08-26 US disclosed
US-5587161-A TWO COMPONENT SYSTEM INCLUDING ANTIBODY OR ANTIGEN BINDING FRAGMENT CONJUGATED TO CARBOXYPEPTIDASE G ENZYME, COMPOUND CONVERTIBLE TO CYTOTOXIC DRUG UNDER INFLUENCE OF ENZYME ZENECA LIMITED (GB) 1996-12-24 US disclosed
EP-0651740-A1 AMINO ACID LINKED NITROGEN MUSTARD DERIVATIVES AND THEIR USE AS PRODRUGS IN THE TREATMENT OF TUMOURS ZENECA LIMITED (GB) 1995-05-10 EP disclosed
US-5405990-A For use in antibody directed enzyme prodrug therapy; cytotoxic parent nitrogen mustard; antitumor agents ZENECA LIMITED (GB) 1995-04-11 US disclosed
WO-1994002450-A1 AMINO ACID LINKED NITROGEN MUSTARD DERIVATIVES AND THEIR USE AS PRODRUGS IN THE TREATMENT OF TUMOURS ZENECA LIMITED (GB) 1994-02-03 WO disclosed